<DOC>
	<DOC>NCT00660595</DOC>
	<brief_summary>This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1.</brief_summary>
	<brief_title>Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>In the opinion of the Investigator, requirement for treatment for an acute episode of schizophrenia, schizoaffective disorder or schizophreniformic psychosis (according to DSMIV diagnostic criteria), Positive and Negative Symptoms Scale (PANSS) ≥ 65, CGI ≥ 4 Pregnancy or lactation Inpatients/hospitalized &gt; 7 days before enrollment Known intolerance or lack of response to quetiapine fumarate or risperidone, as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective psychosis</keyword>
	<keyword>Schizophreniformic psychosis</keyword>
	<keyword>Pilot study</keyword>
	<keyword>Quetiapine Prolong</keyword>
	<keyword>Risperidone</keyword>
</DOC>